


**EINLADUNG**  
**THORAKOSKOPIEKURS**  
**20. - 22. OKTOBER 2022**  
**HALLE (SAALE)**



KRANKENHAUS  
**ST. ELISABETH &  
ST. BARBARA**

## Management of Pneumothorax (PTX): the role of thoracoscopy

**Prof. Marios Froudarakis, MD, PhD,**  
**Head, Department of Pulmonology**  
**University Hospital of Saint-Etienne, Fr**  
**[marfroud@gmail.com](mailto:marfroud@gmail.com)**



# Spontaneous pneumothorax (SP): classification

---

- 1. SP
  - primary SP (PSP):
    - no known underlying lung disease
  - secondary SP (SSP):
    - COPD, Tbc, catamenial, cystic fibrosis etc.
- 2. Iatrogenic/traumatic



The poster features a dark, textured background on the left with white text. On the right, there is a yellow vertical bar containing a white cross logo with a geometric design inside. Below the logo, the hospital name is written in black text.

**EINLADUNG**  
**THORAKOSKOPIEKURS**  
**20. - 22. OKTOBER 2022**  
**HALLE (SAALE)**

KRANKENHAUS  
**ST. ELISABETH &  
ST. BARBARA**

# How can we better manage PSP!

- Difficult question
  - Controversies
    - Definitions
    - Recommendations
    - Beliefs



# Controversies in PTX


**EINLADUNG**  
THORAKOSKOPIEKURS  
20. - 22. OKTOBER 2022  
HALLE (SAALE)




KRANKENHAUS  
ST. ELISABETH &  
ST. BARBARA

## Treat a large PTX: Definition of a large PTX

- >15-20% (Light index)



$$\text{Size PTX(\%)} = (1 - D_L^3 / D_H^3) \times 100$$



# Controversies in the guidelines!



BTS guidelines

ERS statement 2015:

The decision to evacuate air is determined




Figure 2 Flowchart of management of spontaneous pneumothorax.

- Primarily by patient's symptoms
- Secondarily by his ability to carry out his normal life activities
- Lastly by the size of PTX

Tschopp JM et al. ERS guidelines. ERJ 2015;46:321

• McDuff A et al. BTS guidelines. Thorax 2010;65(sup2):ii18=31

# Management of first episode of PSP

- **Therapeutic choices in PSP**

- Remove air from the pleural space
- **Which is the best option to remove air?**
- Observation (do nothing)?!

Stradling P, Pool G. Thorax 1966;21:145  
Brown SGA et al. NEJM 2020;382:405



Noppen et al. AJRCCM 2002;165:1240-4  
Thelle A et al, Eur Respir J 2017;49:1601

Marquette CH et al. Eur Respir J 2014; 43:582  
Brims & Maskell. Thorax 2013; 68:664-9




**EINLADUNG**  
THORAKOSKOPIEKURS  
20. - 22. OKTOBER 2022  
HALLE (SAALE)



KRANKENHAUS  
ST. ELISABETH &  
ST. BARBARA

# Vanderschueren concept of PSP (1980)

- Stage I: normal
- Stage II: small blebs
- Stage III: bullae < 2 cm
- Stage IV: bullae > 2 cm



rupture  
of bulla?






**EINLADUNG**  
THORAKOSKOPIEKURS  
20. - 22. OKTOBER 2022  
HALLE (SAALE)

KRANKENHAUS  
ST. ELISABETH &  
ST. BARBARA

# What is the cause of recurrences?

After bullectomie, recurrence rates are still significant, which means that the problem is not only the bullae/blebs

Courtesy of Pr Olivier Tiffet (St-Etienne)



Courtesy of Prof. Marc Noppen

**EINLADUNG**  
THORAKOSKOPIEKURS  
20. - 22. OKTOBER 2022  
HALLE (SAALE)




KRANKENHAUS  
ST. ELISABETH &  
ST. BARBARA



# PSP: Facts of pathophysiology

- CT Scans
  - 70 - 100% sub-pleural blebs (« empysema-like changes » - ELC 's) in PSP
- ELC 's bilateral in patients with sternotomy
  - (Gobbel 1963, Barnofsky 1957, Ikeda 1988, Donahue 1993, Mittlehner 1992, Lesur 1990)





Courtesy of Pr Olivier Tiffet (St-Etienne)





# PSP: Facts of pathophysiology

Noppen M. Am J Respiratory Care Med 2004;170:680-682



Courtesy of Pr Marc Noppen



**EINLADUNG**  
THORAKOSKOPIEKURS  
20. - 22. OKTOBER 2022  
HALLE (SAALE)



KRANKENHAUS  
ST. ELISABETH &  
ST. BARBARA

# Respiratory Bronchiolitis (RB) in PSP patients?



- Retrospective study in 79 pts
- Results:
  - RB: 70/79 (89%)
  - Interstitial abnormalities: 53/79 (67%)

Cottin V et al. Eur Respir J 1998;12:702

# PSP: inflammation of the pleura?

□ De Smedt Eur Respir J 2004;23:896

**n = 29 PSP - 30 controls**


Table 1. – Lavage cell counts

	PSP per mm <sup>3</sup>	CONTR per mm <sup>3</sup>	p-value
WBC	1973 (547–3040)	159 (74–214)	<0.001
NEU	384 (59–1052)	1 (0–2)	<0.001
EO	243 (120–635)	0 (0–0)	<0.001
BASO	22 (3–48)	0 (0–0)	<0.001
LYMPH	102 (46–201)	27 (14–60)	0.024
MACR	671 (268–919)	118 (47–146)	<0.004
MESO	10 (0–35)	0 (0–2)	0.034

Absolute cell counts per mm<sup>3</sup> in lavage fluid of primary spontaneous pneumothorax (PSP) patients and controls (CONTR) are expressed as median (interquartile range: 25–75). WBC: white blood cell counts; NEU: neutrophils; EO: eosinophils; BASO: basophils; LYMPH: lymphocytes; MACR: macrophages; MESO: mesothelial cells.



# New insights in the pathophysiology of PSP



**EINLADUNG**  
THORAKOSKOPIEKURS  
20. - 22. OKTOBER 2022  
HALLE (SAALE)



KRANKENHAUS  
ST. ELISABETH &  
ST. BARBARA

# PSP: Where is the leak ?



- ✓ *The cause is probably a diffused and extended process of inflammation of the pleura and destruction of the adjacent pulmonary parenchyma*

# PSP recurrences: facts

- Overall (drainage including)
  - 30% (16-57%)
  - **So, 70% no recurrence**
- Recurrence depends on
  - Time: 2 yrs after 1<sup>st</sup> episode
  - Smoking
- Recurrence does not depend on
  - Patient's age
  - The importance of PSP

*Schramel et al. Eur Resp J 1997*



# Recurrence rates after treatment of bullae: Bullectomy vs Pleurodesis

- VATS Bullectomy alone - 25 pts : 20% recurrences  
Bullectomy + Pleurodesis - 24 pts : 4% recurrences  
(cyclin) *Loubani, Respir Med 2000; 94: 888*
- VATS Bullectomy alone - 72 pts : 6% recurrences  
Pleurodesis alone - 37 pts : 0% recurrences  
(talc) *Hatz, Ann Thor Surg 2000; 70: 253*
- VATS Bullectomy alone - 50 pts : 16% recurrences  
Bullectomy + Pleurodesis - 53 pts: 1.9% recurrences  
(electrocauthery) *Horio, Surg Endosc 2002; 16: 630*





# Treatment of bullae

Tschopp JM et al. ERS Statement. Eur Respir J 2015;46:321-35

Bleb/bullectomie should not be performed routinely

- Not more efficient
- Increase cost
- The leak is not necessarily due to a bleb
- No firm proof



# ERS Statement 2015. Surgical procedures



TABLE 5 Surgical procedures for persistent or recurrent primary spontaneous pneumothorax

Strategy	Comment
Routine excision of the apex of the lung	Controversial
Selective excision of blebs or bullae	Controversial as not evidence-based for pulmonologists; general agreement among surgeons
Bullectomy	Controversial but better results than bullae ligation in non-randomised studies
Coverage of staple line with absorbable mesh	To be confirmed
Electro- or cold coagulation of blebs and bullae	Controversial
Endobronchial valves to close persistent air leak	Still anecdotal
Talc poudrage	95% success rate at follow-up; not advisable as sole treatment in cases of significant bullae

# ERS Statement 2015. Recurrence prevention and definitive management: Pleurodesis



TABLE 3 Indications for definitive management of primary spontaneous pneumothorax (PSP)


- Second episode of PSP
- Persisting air leak >3–5 days
- Haemopneumothorax
- Bilateral pneumothorax
- Professions at risk (aircraft personnel, divers)

- 
- Talc poudrage with graded talc is safe and the most cost-effective approach to obtain a diffuse chemical pleurodesis
  - Surgical approach: VATS is preferred to open thoracotomy

# What to do in case of persistent air-leak / recurrence?

## So, why don't we simply perform thoracoscopic pleurodesis to these patients?

Tschopp JM, Schnyder JM, Froudarakis M, Astoul P. Eur Respir J 2009;33:442-3



**EINLADUNG**  
THORAKOSKOPIEKURS  
20. - 22. OKTOBER 2022  
HALLE (SAALE)



KRANKENHAUS  
ST. ELISABETH &  
ST. BARBARA

# Treatment of complicated PSP by simple talcage under thoracoscopy

- Spontaneous Pneumothorax      PSP n=65; SSP n=28
- Short term success rate:      90/93 (97%)
- Mean duration of follow up:    5.1+3.4 (1.5 - 9.2) yrs
- Long term success rate      80/84 (95%)
- No serious complication

*Tschopp et al, Thorax 1997;52:329*



# Talc pleurodesis by medical thoracoscopy



<u>Author</u>	<u>n</u>	<u>failure/relapse</u>
Boutin 1985	100	5 %
Boutin 1991	505	7.3 %
Viskum 1989	99	2.5 %
El Kahwand 1995	200	6 %
Tschopp 2002	59	5%
Gyorik 2007	56	5%

Hallifax R et al, Thorax 2017;72:1121

# Talc pleurodesis by medical thoracoscopy in PTX



- Under deep sedation


Kostroglou A, Kapetanakis EI, Rougeris L, Froudarakis ME, Sidiropoulou T. [Review of the Physiology and Anesthetic Considerations for Pleuroscopy/Medical Thoracoscopy](#). Respiration. 2021 Sep 9:1-15

# Yes, but is this cost-effective?



## European randomized controlled study: Simple Talcage under thoracoscopy (TT) versus drainage (D)

- n = 108 -> 2 groups: TT versus D
- Failures after 5 years
  - TT= 5% vs D=27% (p < .01)
- No difference in complication rates
- No difference in immediate costs
- **Total Cost TT < Cost D (considering recurrences)**



Tschopp JM et al, Eur Respir J 2002;20:1003




Costs<sup>#</sup> of hospitalisation and total costs<sup>#</sup> per patient for thoracoscopic and pleural drainage

	Thoracoscopic talcage	Pleural drainage
Professional (time · day <sup>-1</sup> min)		
Physician (10)	60.20 ± 35	53.05 ± 28
Nursing care (120) <sup>¶</sup>	501.35 ± 288	441.50 ± 237
Materials		
Radiographs	254.15 ± 168	232.25 ± 106
Blood tests	83.15 ± 34	75.60
Drugs	10.75 ± 13	4.65 ± 5
Dressings and chest tube	8.35 ± 6	7.90 ± 5
Clothing and cleaning	24.80 ± 14	21.85 ± 12
Food	126.25 ± 77	115.15 ± 62
Secondary talcage procedure <sup>§</sup>		78.40
Total hospitalisation costs	1069.00 ± 635	1030.35 ± 455
Total costs <sup>f</sup>	1461.10 ± 635	1080.60 ± 455 <sup>+</sup>



Immediate costs



Overall costs (including recurrences)

Simple talc poudrage under medical thoracoscopy is more cost-effective than a simple chest tube treatment

## Secondary SP (SSP)



- Simple aspiration: less successful
- Prevention of recurrences as much as possible: (RR of SSP 50%)
- Thoracoscopic talc poudrage success rate same as PSP: 95%

**Noppen M. Eur Respir J 1997;10:412-417**  
**Tschopp JM. Thorax 1997; 52: 329-332**

Yes, but is this risky?

# Thoracoscopy in COPD with PNO

**Table 2—Procedures, Hemodynamic Changes, Complications, Mortality, and Success\***

Variables	Values
Median time to thoracoscopy, d	4 (range, 3–5)
Median dose of midazolam, mg	2 (range, 1–2.8)
Hemodynamic changes	
Before thoracoscopy	
Heart rate, beats/min	81 ± 9
Systolic BP, mm Hg	120 ± 12
Sao <sub>2</sub> , %	94 ± 2
During thoracoscopy	
Heart rate, beats/min	107 ± 16
Systolic BP, mm Hg	136 ± 10
Sao <sub>2</sub> , %	91 ± 2
Vanderschueren stage	
1	21 (51)
2	2 (5)
3	5 (12)
4	13 (32)
Complications	
Fever	5 (12)
Pain	13 (32)
Cough	26 (63)
Subcutaneous emphysema	27 (66)
Immediate success, %	100
Long-term success, %	95
Mortality at 30 d	4 (10)

FEV <sub>1</sub> , L	Cause of Death	Days Post-MT
0.50	AMI	1
0.70	Pneumonia	13
0.55	COPD	14
0.60	Pneumonia	17

- Deaths due to
  - Respiratory status
  - Comorbidities

**Lee P, et al. Chest 2004; 125: 1315-20**



# Thoracoscopy in COPD with PNO

**Table 1—Demographics of Patients with COPD and SP\***

Variables	Values
Patients, No.	41
Mean age, yr	70.7 ± 7.2
Gender	
Men	38
Women	3
Pack-years	52.8 ± 22.3
FEV <sub>1</sub>	
L	0.88 ± 0.28
% predicted	41 ± 14
FVC	
L	1.70 ± 0.42
% predicted	60 ± 14
FEV <sub>1</sub> /FVC, %	52 ± 12
Body mass index, kg/m <sup>2</sup>	17.2 ± 3.0
Functional status	
NYHA class 3	15 (37%)
NYHA class 4	26 (63%)
Fitness for thoracoscopy	
ASA grade 3	15 (37%)
ASA grade 4	26 (63%)
Median postoperative chest tube drainage, d	4 (range, 3–6.5)
Median length of stay, d	5 (range, 4–7.5)





\*Values given as mean ± SD, unless otherwise indicated.



- 41 Patients with PSP due to COPD were recruited for pleuroscopy and talc poudrage under local anaesthesia
- Pain scores, safety and outcome

**Lee P, et al. Chest 2004; 125: 1315-20**

# Why increased mortality in such patients



**EINLADUNG**  
**THORAKOSKOPIEKURS**  
 20. - 22. OKTOBER 2022  
 HALLE (SAALE)



KRANKENHAUS  
 ST. ELISABETH &  
 ST. BARBARA

# Conclusion: Thoracoscopic pleurodesis

- ✓ Simple talc pleurodesis by thoracoscopy is a safe, mini-invasive and cost-effective technique to prevent recurrences of SP in selected patients
- ✓ Need of deep sedation
- ✓ Treatment of PSP or SSP: prevention of recurrences





**Pr Jean-Marie Tschopp**

**EINLADUNG**  
**THORAKOSKOPIEKURS**  
**20. - 22. OKTOBER 2022**  
**HALLE (SAALE)**



KRANKENHAUS  
**ST. ELISABETH &**  
**ST. BARBARA**

Thank you Jean-Marie  
[marfroud@gmail.com](mailto:marfroud@gmail.com)